Anna Esteve

TL;DR: Life expectancy in HIV-infected patients treated with combination antiretroviral therapy increased between 1996 and 2005, although there is considerable variability between subgroups of patients.

TL;DR: In this article, the authors compared changes in mortality and life expectancy among HIV-positive individuals on combination antiretroviral therapy in 1996-99, 2000-02, and 2003-05, and stratified by sex, baseline CD4 cell count, and history of injecting drug use.

TL;DR: Results suggest that, despite suppressive HAART, active replication persists in some infected individuals and drives immune activation, and the ability of raltegravir intensification to perturb the reservoir that supports active replication has implications for therapeutic strategies aimed at achieving viral eradication.

TL;DR: It is estimated that cART halved the average mortality rate in HIV-infected individuals and was greater in those with worse prognosis at the start of follow-up.

TL;DR: Initiation of cART at a threshold CD4 count of 0.500 × 10(9) cells/L increases AIDS-free survival, and mortality did not vary substantially with the use of CD4 thresholds between 0.300 and 0.200, while Residual confounding may exist.